Curbstone Financial Management Corp Sells 250 Shares of Exact Sciences Co. (NASDAQ:EXAS)

Curbstone Financial Management Corp lowered its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS) by 3.2% in the fourth quarter, Holdings Channel.com reports. The fund owned 7,600 shares of the medical research company’s stock after selling 250 shares during the quarter. Curbstone Financial Management Corp’s holdings in Exact Sciences were worth $427,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Dimensional Fund Advisors LP increased its stake in Exact Sciences by 12.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,002,784 shares of the medical research company’s stock worth $42,389,000 after buying an additional 108,296 shares during the period. Amalgamated Bank increased its position in shares of Exact Sciences by 2.7% during the second quarter. Amalgamated Bank now owns 10,937 shares of the medical research company’s stock worth $462,000 after acquiring an additional 284 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp increased its position in shares of Exact Sciences by 61.2% during the second quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 34,787 shares of the medical research company’s stock worth $1,470,000 after acquiring an additional 13,213 shares during the period. APG Asset Management N.V. raised its stake in shares of Exact Sciences by 40.5% during the second quarter. APG Asset Management N.V. now owns 90,802 shares of the medical research company’s stock valued at $3,580,000 after acquiring an additional 26,155 shares in the last quarter. Finally, MBB Public Markets I LLC bought a new position in Exact Sciences in the second quarter worth approximately $562,000. Institutional investors own 88.82% of the company’s stock.

Insider Buying and Selling

In other Exact Sciences news, CEO Kevin T. Conroy acquired 19,500 shares of the company’s stock in a transaction dated Wednesday, November 13th. The shares were acquired at an average cost of $51.35 per share, with a total value of $1,001,325.00. Following the acquisition, the chief executive officer now directly owns 1,074,191 shares of the company’s stock, valued at approximately $55,159,707.85. The trade was a 1.85 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. 1.36% of the stock is owned by corporate insiders.

Exact Sciences Stock Down 0.5 %

NASDAQ:EXAS opened at $55.68 on Tuesday. The company has a current ratio of 2.12, a quick ratio of 1.93 and a debt-to-equity ratio of 0.72. Exact Sciences Co. has a 12 month low of $40.62 and a 12 month high of $79.62. The firm has a fifty day simple moving average of $57.66 and a 200-day simple moving average of $59.68.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings data on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). Exact Sciences had a negative net margin of 7.95% and a negative return on equity of 6.17%. The firm had revenue of $708.66 million during the quarter, compared to analyst estimates of $716.80 million. Exact Sciences’s revenue was up 12.8% compared to the same quarter last year. As a group, research analysts expect that Exact Sciences Co. will post -1.1 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. BTIG Research lifted their target price on Exact Sciences from $65.00 to $75.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. Stifel Nicolaus lowered their price objective on shares of Exact Sciences from $82.00 to $67.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Bank of America reduced their price target on shares of Exact Sciences from $75.00 to $72.00 and set a “buy” rating for the company in a report on Friday, December 13th. Canaccord Genuity Group dropped their price objective on shares of Exact Sciences from $95.00 to $75.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Finally, Citigroup reduced their price objective on shares of Exact Sciences from $80.00 to $75.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $72.76.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.